Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a...

Keywords

PembrolizumabMedicineIpilimumabInternal medicineClinical endpointAdverse effectRefractory (planetary science)CohortClinical trialMelanomaResponse Evaluation Criteria in Solid TumorsGastroenterologySurgeryPhases of clinical researchCancerImmunotherapy

Affiliated Institutions

Related Publications

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Publication Info

Year: 2014
Type: article
Volume: 384
Issue: 9948
Pages: 1109-1117
Citations: 1743
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1743

OpenAlex

Cite This

APA Style

                            
                                
                                    Caroline Robert, 
                                
                                    Antoni Ribas, 
                                
                                    Jedd D. Wolchok
                                
                                et al.
                            
                            (2014). 
                            Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. 
                            The Lancet
                            , 384
                            (9948)
                            , 1109-1117.
                            https://doi.org/10.1016/s0140-6736(14)60958-2
                        

Identifiers

DOI: 10.1016/s0140-6736(14)60958-2